2024
Patient Characteristics and Practice Variation Associated With New Community Prescription of Benzodiazepine and z‐Drug Hypnotics After Critical Illness: A Retrospective Cohort Study Using the UK Clinical Practice Research Datalink
Mansi E, Rentsch C, Bourne R, Guthrie B, Lone N. Patient Characteristics and Practice Variation Associated With New Community Prescription of Benzodiazepine and z‐Drug Hypnotics After Critical Illness: A Retrospective Cohort Study Using the UK Clinical Practice Research Datalink. Pharmacoepidemiology And Drug Safety 2024, 33: e70056. PMID: 39603606, PMCID: PMC11602247, DOI: 10.1002/pds.70056.Peer-Reviewed Original ResearchConceptsCommunity prescriptionsZ-drugsIllness survivorsRetrospective cohort studyClinical Practice Research Datalink dataPractice variationUK Clinical Practice Research DatalinkClinical Practice Research DatalinkWorsening mental health conditionsCohort studyMultilevel multivariable logistic regressionSurvivors of critical illnessZ-drug prescribingCritical care survivorsPrimary care practicesCritical illnessMental health conditionsZ-drug prescriptionsCritical illness survivorsMultivariate logistic regressionPrescription opioid useCare practicesRisk of adverse eventsHealth conditionsHistory of insomniaImpact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY
Wiedemann M, Speed V, Cunningham C, Higgins R, Curtis H, Andrews C, Fisher L, Hopcroft L, Rentsch C, Mahalingasivam V, Tomlinson L, Morton C, Samuel M, Green A, Wood C, Brown A, Massey J, Walters C, Smith R, Inglesby P, Evans D, Maude S, Dillingham I, Walker A, Morley J, Mehrkar A, Bacon S, Bates C, Cockburn J, Parry J, Hester F, McManus R, Goldacre B, MacKenna B. Impact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY. Open Heart 2024, 11: e002732. PMID: 39214534, DOI: 10.1136/openhrt-2024-002732.Peer-Reviewed Original ResearchConceptsBlood pressure screeningPressure screeningPercentage of patientsHypertension prevalenceHypertension managementPopulation-based cohort studyRecord of hypertensionCardiovascular disease managementClinical subgroupsQOF indicatorsScreening ratesPrimary careGeneral practiceHome statusNHS patientsOlder peopleBlood pressure measurementsCare schemesCohort studyDisease managementImpact of COVID-19COVID-19Framework indicatorsNational qualityNHSIncident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records
Doran W, Tunnicliffe L, Muzambi R, Rentsch C, Bhaskaran K, Smeeth L, Brayne C, Williams D, Chaturvedi N, Eastwood S, Dunachie S, Mathur R, Warren-Gash C. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. BMJ Open Diabetes Research & Care 2024, 12: e003548. PMID: 38272537, PMCID: PMC10823924, DOI: 10.1136/bmjdrc-2023-003548.Peer-Reviewed Original ResearchConceptsRisk of dementiaMild cognitive impairmentOral glucose-lowering therapyDementia riskObservational cohort studyAs-treated analysisGlucose-lowering therapyRisk of incident all-cause dementiaUK adultsCompare risk of dementiaIncident all-cause dementiaType 2 diabetesClinical Practice Research DatalinkActive comparator new user designCohort studyAll-cause dementiaPrimary healthcare recordsIncident dementia riskAssociated with lower riskPotential exposure misclassificationCox proportional hazards regressionMetformin useRisk of confoundingProportional hazards regressionIncident dementiaHerpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study
Tunnicliffe L, Weil R, Breuer J, Rodriguez‐Barradas M, Smeeth L, Rentsch C, Warren‐Gash C. Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study. Movement Disorders 2024, 39: 438-444. PMID: 38226430, PMCID: PMC10922272, DOI: 10.1002/mds.29701.Peer-Reviewed Original ResearchConceptsUS Department of Veterans AffairsCohort studyRisk of incident PDDepartment of Veterans AffairsCox proportional hazards regressionIncident Parkinson's diseaseAssociated with increased riskHistory of HZMatched cohort studyProportional hazards regressionRisk of PDHerpes zosterIncident PDRisk of incident Parkinson's diseaseVeterans AffairsIncident HZUS veteransPD overallHazards regressionPD riskParkinson's diseaseIncreased riskMatched individualsUS DepartmentAssociated with Parkinson's disease
2023
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
Wang A, Shen J, Rodriguez A, Saunders E, Chen F, Janivara R, Darst B, Sheng X, Xu Y, Chou A, Benlloch S, Dadaev T, Brook M, Plym A, Sahimi A, Hoffman T, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury P, Schleutker J, Tammela T, Sipeky C, Auvinen A, Giles G, Southey M, MacInnis R, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch C, Cho K, Mcmahon B, Neal D, Donovan J, Hamdy F, Martin R, Nordestgaard B, Nielsen S, Weischer M, Bojesen S, Røder A, Stroomberg H, Batra J, Chambers S, Horvath L, Clements J, Tilly W, Risbridger G, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning A, Ghoussaini M, Travis R, Key T, Riboli E, Park J, Sellers T, Lin H, Albanes D, Weinstein S, Cook M, Mucci L, Giovannucci E, Lindstrom S, Kraft P, Hunter D, Penney K, Turman C, Tangen C, Goodman P, Thompson I, Hamilton R, Fleshner N, Finelli A, Parent M, Stanford J, Ostrander E, Koutros S, Beane Freeman L, Stampfer M, Wolk A, Håkansson N, Andriole G, Hoover R, Machiela M, Sørensen K, Borre M, Blot W, Zheng W, Yeboah E, Mensah J, Lu Y, Zhang H, Feng N, Mao X, Wu Y, Zhao S, Sun Z, Thibodeau S, McDonnell S, Schaid D, West C, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel A, Drake B, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou Y, John E, Grindedal E, Maehle L, Khaw K, Ingles S, Stern M, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein B, Kerns S, Ostrer H, Teixeira M, Paulo P, Brandão A, Watya S, Lubwama A, Bensen J, Butler E, Mohler J, Taylor J, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink C, Huff C, Pilie P, Yu Y, Bohlender R, Gu J, Strom S, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach R, Brenner H, Chen X, Holleczek B, Schöttker B, Klein E, Hsing A, Kittles R, Murphy A, Logothetis C, Kim J, Neuhausen S, Steele L, Ding Y, Isaacs W, Nemesure B, Hennis A, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo S, Newcomb L, Lin D, Fowke J, Neslund-Dudas C, Rybicki B, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao J, Martinez M, Larkin S, Townsend P, Aukim-Hastie C, Bush W, Aldrich M, Crawford D, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum R, Adjei A, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam A, Keaton J, Hellwege J, Clark P, Jalloh M, Gueye S, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebiyi A, Aisuodionoe-Shadrach O, Ajibola H, Jamda M, Oluwole O, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell S, Roobol M, Jenster G, van Schaik R, Hu J, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss M, Loos R, Zawistowski M, Zöllner S, Lu Z, Van Den Eeden S, Easton D, Ambs S, Edwards T, Mägi R, Rebbeck T, Fritsche L, Chanock S, Berndt S, Wiklund F, Nakagawa H, Witte J, Gaziano J, Justice A, Mancuso N, Terao C, Eeles R, Kote-Jarai Z, Madduri R, Conti D, Haiman C. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nature Genetics 2023, 55: 2065-2074. PMID: 37945903, PMCID: PMC10841479, DOI: 10.1038/s41588-023-01534-4.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesMulti-ancestry genome-wide association studyNovel risk variantsRisk variantsAssociation studiesProstate cancer genome-wide association studiesCancer genome-wide association studyGenome-wide discoveryProstate cancer susceptibility lociGenetic risk scoreCancer susceptibility lociEuropean ancestry menGenetic studiesSusceptibility lociNon-aggressive diseaseEffective risk stratificationAfrican ancestry menProstate cancer riskAncestry groupsProstate cancer casesRisk stratificationAfrican ancestryProstate cancerCancer casesCancer riskExcess mortality in US Veterans during the COVID-19 pandemic: an individual-level cohort study
Weinberger D, Bhaskaran K, Korves C, Lucas B, Columbo J, Vashi A, Davies L, Justice A, Rentsch C. Excess mortality in US Veterans during the COVID-19 pandemic: an individual-level cohort study. International Journal Of Epidemiology 2023, 52: 1725-1734. PMID: 37802889, PMCID: PMC10749763, DOI: 10.1093/ije/dyad136.Peer-Reviewed Original ResearchConceptsExcess mortality ratesExcess mortalityComorbidity burdenHazard ratioCohort studyMortality rateVeterans Aging Cohort Study (VACS) IndexIndividual-level cohort studyVeterans AffairsCOVID-19 pandemicLarge integrated healthcare systemExcess mortality patternsHigher comorbidity burdenLower comorbidity burdenMost frail patientsCharlson Comorbidity IndexObservational cohort studyClinical risk groupsIntegrated healthcare systemLeast frailComorbidity indexFrail patientsPre-pandemic periodMedian ageUS veteransAlcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosisPrognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology
Sarri G, Liu W, Zabotka L, Freitag A, Claire R, Wangge G, Elvidge J, Dawoud D, Bennett D, Wen X, Li X, Rentsch C, Uddin J, Ali M, Gokhale M, Déruaz‐Luyet A, Moga D, Guo J, Zullo A, Patorno E, Lin K. Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology. Clinical Pharmacology & Therapeutics 2023, 114: 604-613. PMID: 37342987, DOI: 10.1002/cpt.2977.Peer-Reviewed Original ResearchConceptsPrognostic factorsUmbrella reviewHigh riskIntensive care unit admissionShort-term adverse outcomesCOVID-19AMSTAR-2 toolSystematic literature reviewCare unit admissionRisk of hospitalizationKey prognostic factorsHigh-risk groupCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 outcomesDisease 2019 pandemicComparative effectiveness researchInternational SocietyCOVID-19 disparitiesUnit admissionLong COVIDMale sexAdverse outcomesOptimal careFemale sexHeart diseaseRacial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans
Vickers-Smith R, Justice A, Becker W, Rentsch C, Curtis B, Fernander A, Hartwell E, Ighodaro E, Kember R, Tate J, Kranzler H. Racial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans. American Journal Of Psychiatry 2023, 180: 426-436. PMID: 37132202, PMCID: PMC10238581, DOI: 10.1176/appi.ajp.21111097.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol consumptionAUD diagnosisHispanic veteransWhite veteransUse disordersPrevalence of AUDAlcohol Use Disorders Identification TestUnhealthy alcohol useICD-10 codesAUDIT-C scoresSelf-reported alcohol consumptionAlcohol-related disordersDiagnosis of AUDDisorders Identification TestMaximum scoreSelf-reported raceElectronic health recordsPrimary outcomeAlcohol consumption levelsPotential confoundersHigh prevalenceMillion Veteran ProgramGreater oddsICD-9Excess Mortality Among Patients in the Veterans Affairs Health System Compared With the Overall US Population During the First Year of the COVID-19 Pandemic
Weinberger D, Rose L, Rentsch C, Asch S, Columbo J, King J, Korves C, Lucas B, Taub C, Young-Xu Y, Vashi A, Davies L, Justice A. Excess Mortality Among Patients in the Veterans Affairs Health System Compared With the Overall US Population During the First Year of the COVID-19 Pandemic. JAMA Network Open 2023, 6: e2312140. PMID: 37155169, PMCID: PMC10167568, DOI: 10.1001/jamanetworkopen.2023.12140.Peer-Reviewed Original ResearchConceptsGeneral US populationVA health care systemHealth care systemComprehensive medical careOverall US populationRate of deathVA populationUS populationDeath rateCohort studyExcess mortalityCare systemCOVID-19 pandemicMedical careVeterans Affairs Health Care SystemVeterans Affairs Health SystemHealth systemVA health systemFirst yearVA health careStandardized mortality rateAdult age groupsVA enrolleesMAIN OUTCOMEGeneral populationEvidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry
Chen F, Madduri R, Rodriguez A, Darst B, Chou A, Sheng X, Wang A, Shen J, Saunders E, Rhie S, Bensen J, Ingles S, Kittles R, Strom S, Rybicki B, Nemesure B, Isaacs W, Stanford J, Zheng W, Sanderson M, John E, Park J, Xu J, Wang Y, Berndt S, Huff C, Yeboah E, Tettey Y, Lachance J, Tang W, Rentsch C, Cho K, Mcmahon B, Biritwum R, Adjei A, Tay E, Truelove A, Niwa S, Sellers T, Yamoah K, Murphy A, Crawford D, Patel A, Bush W, Aldrich M, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern M, Kote-Jarai Z, Govindasami K, Cook M, Chokkalingam A, Hsing A, Goodman P, Hoffmann T, Drake B, Hu J, Keaton J, Hellwege J, Clark P, Jalloh M, Gueye S, Niang L, Ogunbiyi O, Idowu M, Popoola O, Adebiyi A, Aisuodionoe-Shadrach O, Ajibola H, Jamda M, Oluwole O, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah J, Diop H, Van Den Eeden S, Blanchet P, Fowke J, Casey G, Hennis A, Lubwama A, Thompson I, Leach R, Easton D, Preuss M, Loos R, Gundell S, Wan P, Mohler J, Fontham E, Smith G, Taylor J, Srivastava S, Eeles R, Carpten J, Kibel A, Multigner L, Parent M, Menegaux F, Cancel-Tassin G, Klein E, Andrews C, Rebbeck T, Brureau L, Ambs S, Edwards T, Watya S, Chanock S, Witte J, Blot W, Gaziano J, Justice A, Conti D, Haiman C. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. European Urology 2023, 84: 13-21. PMID: 36872133, PMCID: PMC10424812, DOI: 10.1016/j.eururo.2023.01.022.Peer-Reviewed Original Research
2022
Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch C, Justice A, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, Monforte A, Gill J, Ceron D, van Sighem A, Linas B, van der Valk M, Hernán M, Collaboration H. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection. Journal Of The International AIDS Society 2022, 25: e26048. PMID: 36562643, PMCID: PMC9784654, DOI: 10.1002/jia2.26048.Peer-Reviewed Original ResearchConceptsSustained virological responseHCV RNA testingDAA treatmentSVR ratesVirological responseProbability of SVRHepatitis C virus (HCV) cureRoutine HCV RNA testingActing antiviral (DAA) treatmentDAA treatment initiationCD4 cell countDirect antiviral agentsPresence of cirrhosisHCV RNA testEnd of treatmentClinical strataDAA recipientsHIV-HCVSVR assessmentSVR statusHIV acquisitionClinical characteristicsAntiviral treatmentTreatment initiationHCV genotypesAssociation Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosisSurvival analysis of localized prostate cancer with deep learning
Dai X, Park JH, Yoo S, D’Imperio N, McMahon BH, Rentsch CT, Tate JP, Justice AC. Survival analysis of localized prostate cancer with deep learning. Scientific Reports 2022, 12: 17821. PMID: 36280773, PMCID: PMC9592586, DOI: 10.1038/s41598-022-22118-y.Peer-Reviewed Original ResearchConceptsProstate cancer mortalityComposite outcomeCancer mortalityRisk predictionTime-dependent c-statisticsProstate-specific antigen (PSA) testLarge integrated healthcare systemLocalized prostate cancerElectronic health record dataClinical decision-making processProstate cancer patientsIntegrated healthcare systemProstate Cancer Risk PredictionHealth record dataLarge-scale electronic health record dataRisk prediction modelCancer risk predictionAntigen testC-statisticCancer patientsProstate cancerClinical decision systemSurvival analysisVeterans AffairsDeep learningSpironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
Farokhnia M, Rentsch CT, Chuong V, McGinn MA, Elvig SK, Douglass EA, Gonzalez LA, Sanfilippo JE, Marchette RCN, Tunstall BJ, Fiellin DA, Koob GF, Justice AC, Leggio L, Vendruscolo LF. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Molecular Psychiatry 2022, 27: 4642-4652. PMID: 36123420, PMCID: PMC10231646, DOI: 10.1038/s41380-022-01736-y.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-ConsumptionEffect of spironolactoneAlcohol consumptionSpironolactone doseNovel pharmacotherapiesUse disordersHuman studiesLarge integrated healthcare systemHeavy episodic alcohol consumptionAlcohol-induced ataxiaMineralocorticoid receptor antagonistsSelf-reported alcohol consumptionBlood alcohol levelsEpisodic alcohol consumptionIntegrated healthcare systemPharmacoepidemiologic cohort studyPotential new pharmacotherapiesCohort studyAlcohol drinkingReceptor antagonistFemale miceFemale ratsNew pharmacotherapiesRat modelAre infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records
Muzambi R, Bhaskaran K, Rentsch C, Smeeth L, Brayne C, Garfield V, Williams D, Chaturvedi N, Warren-Gash C. Are infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records. Translational Psychiatry 2022, 12: 385. PMID: 36109502, PMCID: PMC9478085, DOI: 10.1038/s41398-022-02145-z.Peer-Reviewed Original ResearchConceptsCognitive declineWhite matter hyperintensity volumeSecondary care recordsAssociation of infectionHistory of infectionPotential structural correlatesEvidence of associationCommon infectionsDementia riskHyperintensity volumeInfection diagnosisCare recordsCognitive impairmentLinear mixed effects modelsCognitive functionVolunteer cohortInfectionMixed effects modelsStructural correlatesUK BiobankLinear regression modelsAssociationEffects modelRegression modelsVisual memoryPotentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old
Guillot J, Rentsch CT, Gordon KS, Justice AC, Bezin J. Potentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old. Pharmacoepidemiology And Drug Safety 2022, 31: 1056-1074. PMID: 35780391, PMCID: PMC9464694, DOI: 10.1002/pds.5506.Peer-Reviewed Original ResearchConceptsLevel of polypharmacyRace/ethnicityPIM prevalencePrevalence of PIMsInappropriate medication useElectronic health recordsCommon PIMsPharmacy fillsPROMPT criteriaInappropriate medicationsOlder patientsMedication usePsychotropic medicationsRefill recordsPolypharmacyPatientsVeterans AffairsMedicationsPrevalenceHealth recordsFiscal year 2016AgeMeaningful differencesSexTarget ageTenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regressionValidation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations
Chen F, Darst BF, Madduri RK, Rodriguez AA, Sheng X, Rentsch CT, Andrews C, Tang W, Kibel AS, Plym A, Cho K, Jalloh M, Gueye SM, Niang L, Ogunbiyi OJ, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah JE, Adjei AA, Diop H, Lachance J, Rebbeck TR, Ambs S, Gaziano JM, Justice AC, Conti DV, Haiman CA. Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. ELife 2022, 11: e78304. PMID: 35801699, PMCID: PMC9322982, DOI: 10.7554/elife.78304.Peer-Reviewed Original ResearchConceptsProstate cancer riskPolygenic risk scoresProstate cancerCancer riskOdds ratioMillion Veteran ProgramRisk scoreRisk stratification toolAge-specific absolute risksAfrican ancestry menCancer odds ratiosVeterans Health AdministrationCase-control studyNonaggressive prostate cancerProstate Cancer FoundationAge-specific riskAssociation of PRSPRS categoriesRisk-stratified screeningVeteran ProgramNational Cancer InstituteEuropean ancestry menStratification toolAbsolute riskEffect modificationAssociations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. The Lancet HIV 2022, 9: e404-e413. PMID: 35659335, PMCID: PMC9647005, DOI: 10.1016/s2352-3018(22)00046-7.Peer-Reviewed Original ResearchConceptsIntegrase strand inhibitorsCause mortalityCohort studyThird drugAntiretroviral drugsMortality rateAntiretroviral Therapy Cohort CollaborationFirst-line ART regimensUK Collaborative HIV CohortART-naive peopleCollaborative HIV CohortAntiretroviral therapy regimensUK Medical Research CouncilMedical Research CouncilCohort CollaborationEfavirenz regimensVirological benefitVirological failureVirological suppressionART regimensHIV cohortHazard ratioRoutine careTherapy regimensUS National Institutes